|
| Tuesday, August 7, 2012 |
|
|
Q&A: MediciNova CEO, Dr. Yuichi Iwaki on His Firm's Pipeline, Upcoming Milestones and Recent Clinical Trial Results |
| Dr. Yuichi Iwaki, President and CEO of Nasdaq listed small-cap MediciNova, Inc. (NASDAQ:MNOV) took the time to answer BioMedReports' questions about his firm's pipeline, upcoming milestones and recent clinical trial results. more info >> |
|
| Thursday, August 2, 2012 |
|
|
Amicus Therapeutics: Strong Catalyst Trade With GlaxoSmithKline And Heavy Insider Buying |
| I like to invest in and trade companies with strong corporate structures that are also equipped with upcoming short term catalysts. more info >> |
|
|
Doomed Dendreon? Many Speculators Shocked By Poor Sales Again |
| Dendreon (DNDN) has been a disastrous holding for many investors who may have been initially optimistic about the company's drug PROVENGE. more info >> |
|
| Wednesday, August 1, 2012 |
|
|
Former Chairman and CEO of Celgene Believes His New Firm Can Become "A Substantial Player" in Biotech |
| No doubt, one of the biggest biotech surprises out of the starting gate this year has been Medgenics Inc. (AMEX:MDGN). The stock ran big shortly after their introduction to the market as shares traded from $2.08 to $16.43 in short order-- an impressive run fueled in part by the company's extremely low float and excited reaction by investors. more info >> |
|
| Tuesday, July 31, 2012 |
|
|
Pluristem Therapeutics' New Indication for Pulmonary and Lung Disorders Expands Blockbuster Pipeline |
| This morning, Pluristem Therapeutics (NASDAQ:PSTI) is once again making news. This time, with a new way to treat Pulmonary fibrosis; where a person's lungs become so scarred that breathing is impossible. more info >> |
|
|
Pluristem's New Indication for Pulmonary and Lung Disorders Expands Blockbuster Pipeline |
| This morning, Pluristem Therapeutics (PSTI) is once again making news. This time with a new way to treat Pulmonary fibrosis; where a person's lungs become so scarred that breathing is impossible. It strikes 5 million people per year around the world, and 200,000 in the US. Most die because there is no cure. more info >> |
|
| Friday, July 27, 2012 |
|
|
Roth Capital Says Amarin's Approval Provides Visibility for Neptune Reiterates Buy Rating and $10.30 Price Target |
| In a flash note to clients on Friday, Roth Capital Partners' analyst Joseph Pantginis, Ph.D.,says that Thursday's FDA approval for Amarin Corporation's (NASDAQ:AMRN) Vascepa bodes well for Neptune Technologies & Bioressources' (Nasdaq:NEPT) (TSX:NTB) underlying and growing core NKO business as well as the pharmaceutical opportunity with Acasti's CaPre. more info >> |
|
| Thursday, July 26, 2012 |
|
|
Short Squeeze & Speculation Could Push Onyx and Ligand Higher |
| When I last covered Onyx Pharmaceuticals (NASDAQ:ONXX) on June 19th, the company was trading at a market capitalization of approximately $3 billion dollars ahead of a review of Kyprolis (carfilzomib) by the FDA's Oncologic Drugs Advisory Committee (ODAC). more info >> |
|
| Monday, July 23, 2012 |
|
|
Pluristem Poised To Benefit From The Evolution of Regulatory Requirements |
| Trying to find companies that represent the future of the biotech sector can be tricky for investors. The sector currently leads the market because Food and Drug Administration (FDA) regulatory guidance is changing, with restrictions easing, and new guidelines being proposed and implemented. more info >> |
|
|
New Reports Indicate That Brainstorm's Clinical Data is Compelling |
| While BrainStorm Cell Therapeutics (OTCBB:BCLI) is expected to officially release their highly anticipated clinical data to U.S. investors shortly, two widely distributed overnight reports point to strong progress in the results of their mid-stage clinical trials. more info >> |
|
|
|
|
